2013 Conference on Retroviruses and Opportunistic Infections*

March 3-6, 2013; Atlanta, Georgia
Join expert faculty members Joseph J. Eron, Jr., MD; Joel E. Gallant, MD, MPH; William G. Powderly, MD; Kimberly Y. Smith, MD, MPH; Kathleen E. Squires, MD; and Andrew R. Zolopa, MD, for a review of the HIV highlights of this important annual conference.

Clinical Impact of New Data From Atlanta: Antiretroviral Therapy, Epidemiology, Testing, and Prevention


Both doses of MK-1439 monotherapy tested in the study produced similar > 1 log10 decreases in HIV-1 RNA over 7 days.

Released: March 12, 2013

In treatment-naive patients with CCR5-tropic HIV infection, combination of cenicriviroc plus tenofovir DF/emtricitabine associated with generally similar virologic responses at Week 24 compared with efavirenz plus tenofovir DF/emtricitabine, with fewer discontinuations due to adverse events.

Released: March 10, 2013

Randomized noninferiority study in patients with PI, NNRTI, and NRTI experience and/or viral resistance suggests that NRTIs may be safely omitted from a new optimized regimen without compromising efficacy.

Released: March 12, 2013

In interim analysis, lower rates of virologic failure and integrase inhibitor resistance in dolutegravir-treated patients vs those receiving raltegravir, with similar safety profile.

Released: March 10, 2013

Study results validate WHO-recommended second-line therapy of boosted PI plus NRTIs and lend support to a potential new second-line strategy using NRTI-sparing raltegravir-based regimen.

Released: March 10, 2013

Despite high retention and high self-reported adherence, drug levels low in all 3 study arms from outset of trial, and no difference in rates of HIV acquisition compared with placebo.

Released: March 7, 2013

HIV reservoir size declined in patients who received antiretroviral therapy, with most patients achieving undetectable HIV DNA levels within 1 year.

Released: March 6, 2013

Possible functional cure described in 26-month-old child, who had detectable plasma HIV-1 RNA and PBMC HIV-1 DNA at birth to mother who did not receive ART during pregnancy, was treated with triple-therapy ART by 31 hours after birth and discontinued ART at age 18 months.

Released: March 7, 2013

Although sustained activation of HIV transcription was observed in CD4+ T cells, vorinostat did not induce any changes in HIV DNA, suggesting that additional strategies need to be explored for elimination of latently infected cells.

Released: March 5, 2013

Few differences reported from subset analyses of 2 phase III trials including efficacy and discontinuation rates of dolutegravir-based regimens compared with efavirenz- and raltegravir-based regimens

Released: March 13, 2013

More than one third of patients in cohort did not have genotypic resistance tests before antiretroviral therapy in most recent period.

Released: March 8, 2013

In this large, prospective cohort study, exposure to efavirenz in the first trimester was associated with an increased risk of neurologic birth defects, and exposure to zidovudine was associated with an increased risk of congenital heart defects.

Released: March 7, 2013

Data suggest that racial disparities in HIV incidence among MSM may be explained by partner or other susceptibility factors but not by individual risk behaviors or knowledge of partner’s serostatus.

Released: March 8, 2013

Similar high rates of virologic suppression through Week 24 in each arm, but serum creatinine increases and BMD decreases were smaller in the tenofovir alafenamide arm than in the tenofovir DF arm.

Released: March 8, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Educational grant provided by:
Gilead Sciences
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?